BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study

  ALX Oncology will partner with pharma giant Merck to evaluate a combination of its CD47 inhibitor with Keytruda as a potential treatment for patients with Head & Neck Squamous Cell Carcinoma.

  September 22, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  150+ Nations Join WHO Effort to Fairly Distribute COVID-19 Vaccine Across the Globe

  More than 150 countries have signed on to a World Health Organization program to ensure global access to a COVID-19 vaccine, however, the United States, Russia and China refrained from signing the agreement.

  September 22, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Biopharma Update on the Novel Coronavirus: September 25

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.

  September 22, 2020

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Samsung Biologics Teams Up with AstraZeneca to Propel Commercial Manufacturing

  Samsung Biologics and AstraZeneca announced on Monday that they have entered a long-term supply agreement, expected to be valued at approximately $330 million.

  September 22, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  Drug Development

  AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

  Tagrisso demonstrated an 82% reduction in the risk of central nervous system recurrence or death. The safety and tolerability of the product in the Phase III trial was consistent with previous trials in the metastatic EGFRm NSCLC setting.

  September 22, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  Policy

  Biopharma Update on the Novel Coronavirus: October 2

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 2, 2020.

  September 22, 2020

   · 

  2 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  Promising but Not Clinically Significant, Vaccinex’s Huntington’s Drug Misses the Mark

  Vaccinex announced topline data from the early manifest treatment arm of its Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease.

  September 22, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  NIH Awards Health Tech Companies with Grants to Develop COVID-19 Apps and Solutions

  The U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the COVID-19 pandemic.

  September 22, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  FDA Accepts BLA for bluebird and BMS’ Multiple Myeloma CAR-T Treatment

  Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review.

  September 22, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Biopharma Update on the Novel Coronavirus: September 23

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.

  September 22, 2020

   · 

  5 min read

   · 

  BioSpace Editorial Staff